HomeCompareSCPH vs PLD

SCPH vs PLD: Dividend Comparison 2026

SCPH yields 35.27% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.73M in total portfolio value· pulled ahead in Year 7
10 years
SCPH
SCPH
● Live price
35.27%
Share price
$5.67
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.6K
Annual income
$27,157.20
Full SCPH calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — SCPH vs PLD

📍 PLD pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCPHPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCPH + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCPH pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCPH
Annual income on $10K today (after 15% tax)
$2,998.24/yr
After 10yr DRIP, annual income (after tax)
$23,083.62/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,015,032.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCPH + PLD for your $10,000?

SCPH: 50%PLD: 50%
100% PLD50/50100% SCPH
Portfolio after 10yr
$3.04M
Annual income
$2,388,941.19/yr
Blended yield
78.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

SCPH
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Price Target
$8.12
+43.2% upside vs current
Range: $5.35 — $13.00
Altman Z
-7.3
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCPH buys
0
PLD buys
0
No recent congressional trades found for SCPH or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCPHPLD
Forward yield35.27%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$178.6K$5.91M
Annual income after 10y$27,157.20$4,750,725.19
Total dividends collected$129.2K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$8.12$136.00

Year-by-year: SCPH vs PLD ($10,000, DRIP)

YearSCPH PortfolioSCPH Income/yrPLD PortfolioPLD Income/yrGap
1$14,227$3,527.34$11,241$540.96+$3.0KSCPH
2$19,913$4,690.15$13,019$991.13+$6.9KSCPH
3$27,442$6,135.14$15,801$1,870.97+$11.6KSCPH
4$37,265$7,901.67$20,609$3,701.21+$16.7KSCPH
5$49,902$10,028.00$29,919$7,867.97+$20.0KSCPH
6$65,945$12,549.99$50,631$18,617.74+$15.3KSCPH
7← crossover$86,061$15,499.75$105,528$51,352.20$19.5KPLD
8$110,989$18,904.51$287,364$174,449.42$176.4KPLD
9$141,544$22,785.49$1,081,760$774,280.77$940.2KPLD
10$178,609$27,157.20$5,908,209$4,750,725.19$5.73MPLD

SCPH vs PLD: Complete Analysis 2026

SCPHStock

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Full SCPH Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this SCPH vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCPH vs SCHDSCPH vs JEPISCPH vs OSCPH vs KOSCPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.